Moving beyond the traditional silos of patents, trademarks, and copyrights to a dialogue about how the intellectual property system as a whole can champion design in the 21st century.
Major New York broadcasters eager to shut down streaming television service Aereo have petitioned the Second Circuit Court of Appeals for an en banc review of a ruling that upheld a lower court decision denying an injunction against the broadcasting startup.
The U.S. Patent and Trademark Office in Silicon Valley's arrival is a big deal for patent lawyers and companies who count intellectual property among their most valuable assets.
Attorneys for companies across the U.S. deal with litigation involving so-called "patent trolls" on a regular basis, but recently Alan Schoenbaum, general counsel for Rackspace, has been going online to lay out his anti-troll strategy in public.
Darren W. Saunders, a partner at Manatt, Phelps & Phillips, and Alpa V. Patel, an associate with the firm, write that in the absence of fashion-specific legislation, fashion companies have turned to trademark/trade dress law. However, unlike copyright and design patent laws intended to reward artistic achievement and originality, trademark law is intended to prevent consumer confusion. As a result, proof of a trademark violation can be far more burdensome.
More than half of the patent litigation cases filed in the U.S. in 2012 were brought by companies whose sole purpose is to license patents—so-called "patent trolls"—according to a new study.
According to attorney William Trueba Jr., patent litigation usually involves dedicating resources early in the case; a fact that may thwart the intent of the SHIELD Act.
A Federal Trade Commission agreement with Google Inc. could profoundly impact IP litigation involving standard essential patents.
Tensions between the president of Saint Louis University and its faculty made an unexpected turn into the realm of copyright law—and the university's general counsel is at the center of the storm.
When India's Supreme Court ruled that Novartis AG's cancer drug Gleevec was not sufficiently innovative to merit a patent, the decision revolved around a practice the pharmaceutical industry refers to as "life-cycle management" and which public health advocates call "evergreening."
Corporate Counsel Membership Program
Receive exclusive offers and discounts today!
- Digital editions of Corporate Counsel Magazine
- Corporate Counsel eNewsletters
- Discounts on books, events, online CLE and research